Laddar populära aktier...
SIMRIS GROUP INTERIM REPORT JANUARY-SEPTEMBER 2024
Simris Group AB (publ) (“Simris Group” or the “Company”) announced today that payments from the previously announced and agreed loan facilit...
Simris Group announces that the company's major owner and chairman Steven Schapera has passed away after complications after surgery.
Simris Group AB (publ) ("Simris Group" or the "Company") confirms that its wholly owned Berlin-based subsidiary Simris Biologics GmbH, in co...
SIMRIS GROUP INTERIM REPORT JANUARY-JUNE 2024
Simris Group AB (publ) ("Simris Group" or the "Company") today confirms that its wholly owned Berlin-based subsidiary, Simris Biologics GmbH...
Simris Group AB (publ), reg. no. 556841–9187 (the "Company"), held its annual general meeting on 28 June 2024.
English version follow after the Swedish version.
SIMRIS GROUP INTERIM REPORT JANUARY-MARCH 2024
SIMRIS GROUP AB ANNOUNCED TODAY THAT THE BOARD HAS DECIDED TO MOVE THE COMPANY'S ANNUAL GENERAL MEETING FROM MAY 29, 2024 TO JUNE 28, 2024
Simris Group AB (publ) (“Simris Group” or the “Company”) today announces that the directed issue of convertible debentures (the “Convertible...
Simris Group AB has published its annual report for the 2023 financial year.
Simris Group AB and The Brand Laboratories FZ have agreed to extend the term of the existing flexible funding facility.
Simris Group AB (publ), reg. no. 556841–9187 (the "Company") held an extraordinary general meeting on 5 April 2024.
The board of directors of Simris Group AB (publ) (“Simris Group” or the “Company”) has today resolved to change the terms of the directed is...
The board of directors of Simris Group AB (publ) (“Simris Group” or the “Company”) has today resolved on a directed issue of convertible deb...
Simris Group AB has today, March 12th, 2023, announced the appointment of Dr.
The Simris Board of Directors have resolved to temporarily pause production operations at its microalgae facility in Hammenhög, Sweden.
SIMRIS GROUP YEAR-END REPORT JANUARY-DECEMBER 2023
Simris Group AB (publ) ("Simris" or the "Company") today confirms that it has signed a non-binding Heads of Terms (HOT) agreement with an ex...
Simris Group AB (publ), reg. no. 556841–9187 (the "Company") held an extraordinary general meeting on 20 December 2023.
Simris Group AB (publ) ("Simris Group" or the "Company") today confirms that its subsidiary company, Simris Biologics GmbH, has signed a Mat...
Simris Group AB (publ), reg. no. 556841–9187 (the "Company") will hold an extraordinary general meeting on 20 December 2023 at 10:15.
The board of directors of Simris Group AB (publ) ("Simris Group" or the "Company") proposes that a general meeting on 20 December 2023 resol...
Simris Group AB (publ) ("Simris Group" or the "Company") today confirms that its wholly owned subsidiary Simris Biologics GmbH based in Berl...
Simris Group: Interim Report January - September 2023
Simris Group AB (publ) ("Simris Group" or the "Company") today confirms that it has appointed Reviate LLC (www.
The board of directors of Simris Group AB (publ) ("Simris Group" or the "Company") has today, based on the authorisation from the annual gen...
The fully guaranteed rights issue (“Rights Issue”) and the directed issue ("Directed Issue") in Simris Group AB (publ) (“Simris Group” or th...
The Board of Directors of Simris Group AB (publ) (“Simris Group” or "Company") announces the outcome of the Rights Issue of shares with pref...
The preliminary outcome of the Rights Issue in Simris Group AB (publ) (“Simris Group” or the “Company”), the subscription period of which en...
Under 2022 inledde Simris Group en satsning som ska göra bolaget till ett lönsamt biofarmabolag.
Julian Read, VD för Simris Group AB klargör det strategiska fokuset för Bolaget, affärsmodellen för dess Antibody Drug Conjugate (ADC)-produ...
Simris has signed a Letter of Intent (LOI) to secure the production of microalgae biomass via a manufacturing collaboration agreement with P...
Simris Biologics confirms it has submitted a new patent application covering the optimisation of microcystin-based Antibody Drug Conjugate (...
Simris Group AB (“Simris Group” or the “Company”) today, on July 31, 2023, announces the information memorandum relating to the Company's up...
Simris Group forecasts that Simris Biologics will generate annual sales revenue of €3.
Simris Group confirms that Dr Heike Enke, Chief Science Officer for non-ADC Technologies within Simris Biologics, will, as of 31st July, be ...
Simris Group confirms that 100 % of its upcoming SEK 24,3 million rights issue now is underwritten with 8,8 precent in subscription commitme...
Simris Group AB (the "Company") held an extraordinary general meeting on 24 July 2023.
Simris Group Interim Report January-June 2023
This letter from Julian Read, CEO of Simris Group AB, shares his thoughts around the transformation of the company from a struggling Omega-3...
I detta brev delar Julian med sig av sina tankar kring omvandlingen av företaget från en tuff kamp att bryta ny mark för Omega-3 till ett sp...
Simris Group AB (publ), org.nr 556841–9187 (”Bolaget”) håller extra bolagsstämma den 24 juli 2023 klockan 10.
Simris Group meddelar härmed att publiceringen av bolagets delårsrapport för andra kvartalet 2023, perioden 1 januari - 30 juni 2023, kommer...
Styrelsen för Simris Group AB (publ) (“Simris Group” eller ”Bolaget”) föreslår att en extra bolagsstämma (den ”Extra Bolagsstämman”) besluta...
Villkorat av aktieägarnas godkännande vid en extra bolagsstämma har Simris Group AB och The Brand Laboratories FZ kommit överens om att förl...
Simris Group AB ("Bolaget") höll Årsstämma den 29 maj 2023.
SIMRIS GROUP DELÅRSRAPPORT JANUARI-MARS 2023
Simris Group AB (publ), bekräftar att styrelsen har godkänt ett erbjudande från de tidigare ägarna av Cyano Biotech att förlänga förfallodag...
Simris Group AB (publ), bekräftar att de har fått sin största enskilda order någonsin på fucoxantinrik algbiomassa värd cirka 4,0 MSEK.
Simris Group AB (publ), bekräftar lanseringen av sina nya Omega 3-produkter i USA via Amazon.
Simris Group AB (publ), org.nr 556841–9187 (”Bolaget”) håller årsstämma den 29 maj 2023 klockan 10.
Simris Group AB (publ), är glada att kunna tillkännage en ökning med upp till €150 000 till sin flexibla finansieringsfacilitet med The Bran...
SIMRIS GROUP AB MEDDELADE IDAG ATT STYRELSEN BESLUTAT ATT FLYTTA BOLAGETS ÅRSSTÄMMA FRÅN DEN 15 MAJ 2023 TILL DEN 29 MAJ 2023
Simris Group AB ar publicerat sin årsredovisning för verksamhetsåret 2022.
Simris Group AB (publ), meddelar idag att sedan återstarten av verksamheten vid sin algfarm i Hammenhög, Sverige i januari, att tillväxttakt...
Simris Alg AB (publ), meddelar idag att företagets namn officiellt har ändrats till Simris Group AB inom det svenska aktiebolagsregistret (B...
Simris Alg ab Signs Partnership Agreement With Lonza Ltd to Promote Its Adc Payload Technology
Simris Alg AB (publ) ("Bolaget") höll extra bolagsstämma den 6 mars 2023.
• Strategiskt samarbetsavtal för att kommersialisera Simris nya ”payload” plattform för Antibody-Drug Conjugates (ADCs).
· Simris Alg AB recently proposed to Shareholders to change the name of the parent company from Simris Alg AB to Simris Group AB.
· Simris Alg AB föreslog nyligen för aktieägarna för att ändra moderbolagets namn från Simris Alg AB till Simris Group AB.
· The patent provides broad protection for a platform technology covering the modification of microcystins; a novel ADC payload class wi...
· Patentet ger ett brett skydd för en plattformsteknologi som täcker modifiering av mikrocystiner; en ny ADC-nyttolastklass med ett unikt...
Rättelsen avser den svenska versionen av bolagets bokslutskommuniké.
Simris Alg bokslutskommuniké januari - december 2022
Simris Alg year-end report January-December 2022
Notice of extraordinary general meeting of Simris Alg AB (publ) Simris Alg AB (publ), org.
Simris Alg AB (publ), today announces that it proposes to change its name to Simris Group AB.
Simris Alg AB (publ), meddelar idag att de föreslår att byta namn till Simris Group AB.
Simris Alg AB (publ), tillkännagav idag en ökning på 0,5 miljoner euro till sin flexibla finansieringsfacilitet med The Brand Laboratories, ...
Simris Alg AB (publ), today announced a €0.5m increase to its flexible funding facility with The Brand Laboratories, a company associated wi...
Simris Alg AB (publ) offentliggjorde idag den svenska lanseringen av sin nya, förbättrade Omega-3-produkt innehållande både EPA och DHA som ...
Simris Alg AB (publ) today announced the launch in Sweden of its newly reformulated Omega-3 product containing both EPA and DHA which, for t...
Simris Alg delårsrapport januari - september 2022
Simris Alg interim report January-September 2022
The Board of Directors of Simris ALG AB (publ) ("Simris" or the "Company") has today, with the support of authorization from the Annual Gene...
Simris Alg AB (publ), today announced the successful completion of its acquisition of Cyano Biotech GmbH, a profitable, privately held Berli...
Simris Alg interim report January-June 2022
Simris Alg delårsrapport januari - juni 2022
Simris Alg AB (publ), is pleased to announce that it entered into a binding Letter Of Intent (“LOI”) to acquire 100% of the shares in Cyano ...
Simris Alg AB (publ), meddelar att de ingick en bindande avsiktsförklaring (“LOI”) om att förvärva 100 % av aktierna i Cyano Biotech GmbH de...
Simris Alg AB hereby provides a CEO letter that covers the strategic direction set out by the Board where Simris will enter high profit sect...
Simris Alg AB hereby announces that the company has entered into an agreement with Amudova AB regarding the service as Certified Adviser.
The annual general meeting of Simris Alg AB (publ) was held on Wednesday, 25 May 2022.
Simris Alg AB (publ) (“Simris Alg” or the “Company”) has carried out a rights issue of B shares to an amount of approximately SEK 25.
The Rights Issue of approximately SEK 25.1 million in Simris Alg AB (publ) (“Simris Alg” or the “Company”), which was announced on March 23,...
The preliminary outcome of the rights issue in Simris Alg AB (publ) (“Simris Alg” or the “Company”), the subscription period of which ended ...
Notice of annual general meeting Tid: 25 maj 2022 klockan 11.
Simris Alg interim report January-March 2022
Simris Alg AB has published its annual report for the 2021 financial year.
Simris Alg AB (”Simris Alg” or ”the Company”) has produced an investment memorandum regarding the Company’s Rights Issue, which was made pub...
Styrelsen för Simris Alg har beslutat att ändra kommunikationsspråk till engelska till följd av att bolaget har en internationell styrelse d...
Simris Alg meddelar idag att styrelsen beslutat att flytta fram bolagets årsstämma till den 25 maj 2022.
Simris Alg meddelar härmed att publiceringen av bolagets delårsrapport för första kvartalet 2022, perioden 1 januari - 31 mars 2022, kommer ...
Fredagen den 8 oktober 2022 hölls extra bolagsstämma i Simris Alg AB (publ).
Simris Alg AB är glada att kunna tillkännage utnämningen av Julian Read till rollen som verkställande direktör (VD) för företaget, med start...
Styrelsen i Simris Alg AB (”Simris Alg” eller ”Bolaget”) har idag den 23 mars 2022, villkorat av godkännande vid extra bolagsstämma den 8 ap...